Cite
MLA Citation
Manish Patel et al.. “313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms.” Journal for immunotherapy of cancer, vol. 8, n.d., p. A340. http://access.bl.uk/ark:/81055/vdc_100144723823.0x000004